---
title: "Rituximab in Autoimmune Myasthenic Syndromes: Real‑World Outcomes in MG and LEMS"
id: "medrxiv-12-rituximab-for-autoimmune-myasthenic-syndromes-a-retrospective-cohort-study-in"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-12-rituximab-for-autoimmune-myasthenic-syndromes-a-retrospective-cohort-study-in"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.18.26360320v1?rss=1"
published_at: "2026-08-21T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Rituximab in Autoimmune Myasthenic Syndromes: Real‑World Outcomes in MG and LEMS
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-12-rituximab-for-autoimmune-myasthenic-syndromes-a-retrospective-cohort-study-in
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.18.26360320v1?rss=1)
- **Published At:** 2026-08-21T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This single-center retrospective cohort evaluated **rituximab (RTX)** in patients with autoimmune neuromuscular junction disorders treated between 2011 and 2021. The cohort comprised 64 patients with **myasthenia gravis (MG)** and 5 with **Lambert-Eaton myasthenic syndrome (LEMS)**. - Clinical outcomes were recorded using the **Myasthenia Gravis Foundation of America Post-Intervention Status (MGFA-PIS)**, counts of rescue therapies, occurrence of myasthenic crises, and daily **steroid** dose at 1- and 2-year follow-ups versus baseline. - MGFA-PIS showed improvement at both 1-year and 2-year follow-up compared with baseline, indicating a stabilized or improved clinical course after RTX treatment. - Incidence rates of rescue therapies per 100 person-months decreased from 15.0 (95% CI 11.8–18.8) at baseline to 7.5 (4.7–12.3) at 1 year and to 4.3 (2.5–7.8) at 2 years. - The proportion of patients without myasthenic crises within one year increased from 49 (86.0%) at baseline to 55 (96.5%) at 1-year follow-up. - Median (IQR) daily steroid dose declined from 10 (5–22.5) mg/day at baseline to 4 (0–10) mg/day at 1 year and 2.5 (0–10) mg/day at 2 years, suggesting steroid-sparing benefit. - The cohort included patients with thymoma-associated MG; RTX effects were reported across the population including these patients. - Safety and side-effect details were collected but specific adverse event rates or individual side-effect data were not reported in the abstracted source. - Study limitations inherent to retrospective single-center design and restricted raw-data sharing under current ethical approvals were noted; ethics approval was granted by Charité – University Medical Center Berlin (EA1/260/19). - Authors declared various competing interests with pharmaceutical companies; raw data are not publicly available but may be requested per institutional policies and ethics constraints.
## Clinical Analysis & Structured Key Points
Rituximab for autoimmune myasthenic syndromes: a retrospective cohort study in myasthenia gravis and Lambert-Eaton myasthenic syndrome | medRxiv Skip to main content Rituximab for autoimmune myasthenic syndromes: a retrospective cohort study in myasthenia gravis and Lambert-Eaton myasthenic syndrome Roxanna Chamani Cheri , View ORCID Profile Ulrike Grittner , Paolo Doksani , Carla Dusemund , Lea Gerischer , Meret Luise Herdick , Sarah Hoffmann , Sophie Lehnerer , Frauke Stascheit , Maike Stein , View ORCID Profile Andreas Meisel , View ORCID Profile Philipp Mergenthaler doi: https://doi.org/10.64898/2026.08.18.26360320 Roxanna Chamani Cheri Charite - University Medical Center Berlin Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ulrike Grittner Charite - University Medical Center Berlin Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ulrike Grittner Paolo Doksani Charite - University Medical Center Berlin Find this author on Google Scholar Find this author on PubMed Search for this author on this site Carla Dusemund Charite - University Medical Center Berlin Find this author on Google Scholar Find this author on PubMed Search for this author on this site Lea Gerischer Charite - University Medical Center Berlin Find this author on Google Scholar Find this author on PubMed Search for this author on this site Meret Luise Herdick Charite - University Medical Center Berlin Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sarah Hoffmann Charite - University Medical Center Berlin Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sophie Lehnerer Charite - University Medical Center Berlin Find this author on Google Scholar Find this author on PubMed Search for this author on this site Frauke Stascheit Charite - University Medical Center Berlin Find this author on Google Scholar Find this author on PubMed Search for this author on this site Maike Stein Charite - University Medical Center Berlin Find this author on Google Scholar Find this author on PubMed Search for this author on this site Andreas Meisel Charite - University Medical Center Berlin Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Andreas Meisel Philipp Mergenthaler Charite - University Medical Center Berlin Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Philipp Mergenthaler For correspondence: philipp.mergenthaler{at}charite.de Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract INTRODUCTION Myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) are autoimmune diseases of the neuromuscular junction resulting in fatigable muscle weakness. Rituximab (RTX) is used to treat patients refractory to standard immunosuppression, but evidence for its efficacy remains inconsistent. Here, we analyzed real-world data on the clinical course and side effects of RTX in MG and LEMS patients. METHODS This was a single-center study of all patients diagnosed with MG (n=64) or LEMS (n=5) treated with RTX from 2011 until 2021. Outcomes of RTX treatment were recorded retrospectively with Myasthenia Gravis Foundation of America Post-Intervention Status (MGFA-PIS), number of rescue therapies, myasthenic crises, and steroid dose at 1-year and 2-year follow-ups. RESULTS MGFA-PIS improved at both 1-year (y) and 2-y follow-up compared with baseline. Incidence rates of rescue therapies per 100 person-months (95% CI) decreased from 15.0 (11.8-18.8) at baseline to 7.5 (4.7-12.3) at 1-y and 4.3 (2.5-7.8) at 2y-follow-up. The number of patients without myasthenic crises within one year increased from baseline (49, 86.0%) to 1y-follow-up (55, 96.5%). Median (IQR) daily steroid dose decreased from 10 (5-22.5) mg/d at baseline to 4 (0-10) mg/d at 1y-follow-up, and to 2.5 (0-10) mg/d at 2y-follow-up. CONCLUSION This study indicates that RTX was associated with a stabilized clinical course and decreased steroid use in patients with autoimmune myasthenic syndromes, including those with thymoma-associated MG. Our data suggest that therapeutic benefit is apparent within the first year of treatment and is maintained through two years. Competing Interest Statement P.D. has received travel, accommodation and meeting expenses from Argenx, and UCB; he has received speaker's honoraria and honoraria for attendance at advisory boards from Alexion Astra Zeneca Rare Disease, argenx and UCB; he received institutional financial research support from Argenx. C.D. has received speaker's honoraria from Alexion and UCB and received travel/accommodation expenses and honoraria for attendance at advisory board from Argenx. L.G. has received speaker honoraria and/or travel and congress fees from Alnylam, Alexion, Roche and UCB and is a shareholder of RareLink digital health GmbH. M.L.H. has received speaker's honaria from argenx and alexion and a honoraria for attending advisory boards from alexion. S.H. has received speaker's honoraria, consulting fees or institutional financial research support from Alexion, argenx, UCB, Grifols, Merck, Novartis, Roche and Johnson&Johnson and is member of the medical advisory board of the German Myasthenia Society (DMG e.V.). S.L. received travel/accommodation/meeting expenses from Alexion Astra Zeneca Rare Disease, Argenx, Johnsson&Johnsson, and UCB; she received speaking honoria and honoria for attendance at advisory boards from Alexion Astra Zeneca Rare Disease, Argenx, Biogen, Hormosan, Huma, Johnsson&Johnsson, Merck, Roche, StreamedUp and UCB; she received financial research support (paid to her institution) from Ad Scientiam, Alexion Pharmaceuticals, Argenx, Hormosan and UCB; she is shareholder of RareLink digital health GmbH and mamahealth GmbH.. F.S. received travel/accommodation/meeting expenses from Alexion Pharmaceuticals and argnx and received speaking honoria and honoria for attendance at advisory boards from Alexion Pharmaceuticals, argenx, UCB pharma, Takeda and Octapharma and received research grants from Alexion Pharmaceuticals, argenx, Cytel and Octapharma; she serves as a member of the medical advisory of the German Myasthenia Gravis Society (DMG e.V.). M.S. has received speaker's honoraria and honoraria for attendance at advisory boards from Argenx and Alexion, travel/accommodation/meeting expenses from UCB, and is a shareholder of RareLink digital health GmbH.. A.M. has received honoraria as a speaker/consultant or investigator site payments and financial research support (paid to his institution) from Alexion, AstraZeneca Rare Disease, Amgen, argenx, Axunio, Desitin, Genpharm, Grifols, Hormosan, Immunovant, Johnson & Johnson, Merck, Neopharm, Novartis, Octapharma, Regeneron, Sanofi, and UCB; is chairman of the Association for Research into Myasthenia Syndrome in Germany (VEMSID e.V.); and is a member of the medical advisory board of the German Myasthenia Society (DMG e.V.). P.M. has received travel/accommodation expenses from UCB pharma. All other authors do not report any conflicts of interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was approved by the ethics committee of Charité - University Medical Center Berlin (EA1/260/19). As per the ethics approval, local regulations, and applicable law, informed consent was neither obtained nor required for this retrospective study. The study was conducted in accordance with the Declaration of Helsinki, the German Federal Data Protection Act, and the EU General Data Protection Regulation, and is reported in accordance with the STROBE statement for observational studies. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Ethical approval currently does not permit sharing of raw data. Approval will be sought by the corresponding author upon reasonable request with scientific rationale and sound methodology. Requests for data sharing will be managed in accordance with data access and sharing policies of Charité - University Medical Center Berlin. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . Back to top Previous Next Posted August 21, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Rituximab for autoimmune myasthenic syndromes: a retrospective cohort study in myasthenia gravis and Lambert-Eaton myasthenic syndrome Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Rituximab for autoimmune myasthenic syndromes: a retrospective cohort study in myasthenia gravis and Lambert-Eaton myasthenic syndrome Roxanna Chamani Cheri , Ulrike Grittner , Paolo Doksani , Carla Dusemund , Lea Gerischer , Meret Luise Herdick , Sarah Hoffmann , Sophie Lehnerer , Frauke Stascheit , Maike Stein , Andreas Meisel , Philipp Mergenthaler medRxiv 2026.08.18.26360320; doi: https://doi.org/10.64898/2026.08.18.26360320 Share This Article: Copy Citation Tools Rituximab for autoimmune myasthenic syndromes: a retrospective cohort study in myasthenia gravis and Lambert-Eaton myasthenic syndrome Roxanna Chamani Cheri , Ulrike Grittner , Paolo Doksani , Carla Dusemund , Lea Gerischer , Meret Luise Herdick , Sarah Hoffmann , Sophie Lehnerer , Frauke Stascheit , Maike Stein , Andreas Meisel , Philipp Mergenthaler medRxiv 2026.08.18.26360320; doi: https://doi.org/10.64898/2026.08.18.26360320 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (607) Allergy and Immunology (891) Anesthesia (324) Cardiovascular Medicine (4735) Dentistry and Oral Medicine (473) Dermatology (404) Emergency Medicine (637) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1606) Epidemiology (15760) Forensic Medicine (32) Gastroenterology (1193) Genetic and Genomic Medicine (6941) Geriatric Medicine (723) Health Economics (1048) Health Informatics (4936) Health Policy (1417) Health Systems and Quality Improvement (1728) Hematology (574) HIV/AIDS (1322) Infectious Diseases (except HIV/AIDS) (16213) Intensive Care and Critical Care Medicine (1155) Medical Education (657) Medical Ethics (150) Nephrology (714) Neurology (7124) Nursing (359) Nutrition (1066) Obstetrics and Gynecology (1216) Occupational and Environmental Health (992) Oncology (3557) Ophthalmology (1030) Orthopedics (387) Otolaryngology (442) Pain Medicine (463) Palliative Medicine (138) Pathology (702) Pediatrics (1764) Pharmacology and Therapeutics (729) Primary Care Research (754) Psychiatry and Clinical Psychology (5790) Public and Global Health (9635) Radiology and Imaging (2364) Rehabilitation Medicine and Physical Therapy (1418) Respiratory Medicine (1234) Rheumatology (631) Sexual and Reproductive Health (760) Sports Medicine (571) Surgery (756) Toxicology (106) Transplantation (300) Urology (284)
## Related Clinical Research

- [Nonmedical Switch from MabThera to Truxima Rituximab in Multiple Sclerosis: Effectiveness and Tole](https://medichelpline.com/clinical-feed/medrxiv-21-effectiveness-and-tolerability-of-nonmedical-switching-from-originator-mabthera.md)
- [Efgartigimod for refractory thymoma-associated overlap of stiff-person syndrome and myasthenia gra](https://medichelpline.com/clinical-feed/frontiers-in-immunology-3-case-report-efgartigimod-a-beacon-of-hope-for-overlapping-stiff-person-syndrome.md)
- [Infections and Hypogammaglobulinemia with Low‑Dose Rituximab in Myasthenia Gravis — Full Text Not](https://medichelpline.com/clinical-feed/frontiers-in-immunology-18-infections-and-hypogammaglobulinemia-in-myasthenia-gravis-patients-receiving.md)
- [Concurrent Neurofibromatosis Type 1 and Multiple Sclerosis in a Child: MRI, CSF, and 2024 Criteria](https://medichelpline.com/clinical-feed/pubmed-42485588.md) (DOI: 10.1212/WNL.0000000000218240)
- [VR Headset Pupillometry Detects RAPD and Pathological Anisocoria: Study Results](https://medichelpline.com/clinical-feed/medrxiv-1-pupil-symmetry-and-swinging-light-test-performed-with-vr-headset-for-detection.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.